| TOTAL: $70.42M | |||
| Year to Date: $70.42M | |||
| Company (Symbol)#* | Partner (Country) | Amt. (M) | Details (Date) |
| BioAlliance Pharma SA (France; PARIS:BIO) | Spepharm Holding BV (the Netherlands) | €2.5 ($3.7) |
For the receipt of marketing authorization for Loramyc in the UK and Denmark (1/9) |
| EPIX Pharmaceuticals Inc. (EPIX) | Cystic Fibrosis Foundation Therapeutics Inc. | $1.25 | For the completion of the development of a validated model of a full-length Cystic Fibrosis Transmembrane Conductance Regulator ion channel protein (1/24) |
| Exelixis Inc. (EXEL) | Bristol-Myers Squibb Co. | $20 | For Bristol-Myers' exercised option to develop and commercialize Exelixis' compound XL139 (1/22) |
| Galapagos NV (Belgium; BR:GLPG) | Janssen Pharmaceutica NV | €3.4 $4.97) |
For an achievement in the discovery-stage GTI46 program, one of 19 possible rheumatoid arthritis targets covered under a deal signed by the companies in 2007 (1/25) |
| Genmab A/S (Denmark; CSE:GEN) | GlaxoSmithKline plc (UK) | $34 | For the treatment of the first patient in the Phase II study of ofatumumab in diffuse large B-cell lymphoma in 2007 and for the first patient receiving treatment in the Phase III rheumatoid arthritis program (1/22) |
| Osiris Therapeutics Inc. (OSIR) | JCR Pharmaceuticals Co. Ltd. (Japan) | $0.5 | Osiris is receiving it for JCR's filing notice to start clinical trials with Prochymal in graft-vs.-host disease in Japan (1/7) |
| Seattle Genetics Inc. (SGEN) | Genentech Inc. (NYSE:DNA) | $4 | For Genentech's initiation of a Phase Ib trial of SGN-40 in combination with Rituxan for relapsed follicular or marginal zone non-Hodgkin's lymphoma (1/8) |
| SkyePharma plc (UK; SKYE; LSE:SKP) | Sciele Pharma Inc. | $2 | For the launch of a new formulation of Sular to treat high blood pressure (1/3) |
| Tolerx Inc.* | Genentech Inc. (NYSE:DNA) | ND | Tolerx received the payment for the completion of a Phase Ib study of TRX1 to treat refractory cutaneous lupus erythematosus (1/15) |
| Notes: | |||
| # Unless otherwise indicated, shares are traded on the Nasdaq exchange. | |||
| * Private company. Currency conversions are based on exchange rates at the time of the deal. | |||
| ND = Not disclosed. BR = Brussels Stock Exchange; CSE = Copenhagen Stock Exchange; LSE = London Stock Exchange. | |||
To read more on related topics, click on one of the words below.